Key Takeaways
- Strong quarter, cautious near-term: Revenue grew 40.2% YoY to INR 192.4 crores on near-full capacity and a favorable product mix shift, but management flagged caution for H2 due to global macro headwinds.
- The product mix story is the margin story: A deliberate, multi-quarter shift toward industrial chemicals (now 80% of revenue) has lifted EBITDA margins from 13% to 18% and is the primary lever for sustaining profitability.
- Greenfield expansion is now underway: Environmental clearance is in hand, construction has started at Pakhajan, and INR 64 crores of Phase I capex has already been spent, with commercialization expected by early 2024.
- Customer pull de-risks the capacity bet: Management is confident of hitting 60% utilization on new capacity by 2024-2025 because existing customers are already asking for more product than the company can currently deliver.
- What to watch next quarter: Whether the European energy crisis and US slowdown actually dent order books, any update on Phase I construction milestones, and the trajectory of the product mix shift toward industrial chemicals.
Demand & Macro Environment
- Europe holding up for now: Orders have not been impacted much and management has not observed a significant recession in the region, though the energy crisis warrants caution.
- US slowdown, not recession: A slowdown is visible but no recession is seen currently; management describes the situation as "pretty seasoned" while remaining watchful.
- Near-term caution is explicit: Despite a strong H1, the outlook for coming quarters is cautious due to the energy crisis in Europe, the Russia-Ukraine war, and an inflationary US economy that may cause a short-term demand slowdown.
- Manufacturing headwinds persist: Rising energy costs and supply chain interruptions continue to impact manufacturing activities broadly.
Yayesh Jhaveri: "we haven't heard much of a recession in the Europe because our orders have not been impacted much on these. While in the US, still there is a slowdown, but there is no, we don't see or nor do they see any recession, recession coming in. So we are not seeing right now much of an impact, but maybe on days to come ahead, we might get a much clearer idea. And everything looks, till now we are cautious, but yes, but it looks pretty seasoned."
Product Mix & Margin Structure
- Industrial chemicals now dominate: Over the last six to seven quarters, the product mix has steadily shifted toward industrial chemicals, which now contribute 80% of revenue, up from a lower base.
- Mix shift is the margin engine: EBITDA margins rose from 13% to 18% over the last 10 quarters, driven by continuous quarter-by-quarter improvement and the deliberate pivot away from consumer products toward higher-margin industrial products.
- Mix shift will continue: Management stated the shift toward industrial products will persist as the primary tool to sustain margins going forward.
- Raw material pass-through is structural: The company carries no long-term customer contracts, creating a "cushioning period" where cost inflation can be passed on; when raw material and crude prices correct, benefits are passed back to customers, insulating margins from input price swings.
- No margin commitment given: Management declined to commit to a sustainable EBITDA margin number but pointed to its track record of improving margins quarter-by-quarter.
Yayesh Jhaveri: "we do not have any long-term contracts with the customers at the moment because looking at today's scenario, nobody wants to commit for a longer future. So this is much more of a cushioning period for us, where we can increase, we can pass on our cost to our customers."
Competitive Position & China
- Specialty chemicals are cushioned from China: Chinese material prices are falling in a few commodity chemicals, but the company's specialty rubber chemicals range sees little Chinese competition, providing a buffer.
- Turnover growth signals competitiveness: Management pointed to rising turnover as evidence of improving competitiveness, pushing back on any implication of weakening market position.
- Global market share question deflected: When asked for India's market share in the global rubber chemicals industry, management called it "too difficult" to provide those numbers.
- New China capacity question sidestepped: A question on new capacity coming up in China was deemed "too premature to comment on" and was redirected toward REACH registrations rather than addressed directly.
Yayesh Jhaveri: "In a few chemicals which are more on the commodity side, yes, the prices of the Chinese materials are coming down, but not much on our specialty range. So we are very much cushioned by that because most of our specialty rubber chemicals we do not see much of a Chinese competition."
Greenfield Expansion: Pakhajan Project
- Phase I is live: Environmental clearance has been received for the Greenfield project at Pakhajan, Gujarat, and construction has started in full swing; total cash capex of approximately INR 64 crores was incurred up to H1 FY23.
- Commercialization timeline: The new project is expected to be commercialized after the end of 2023 or in early 2024.
- Phase II on the horizon: Management confirmed a Phase II will follow Phase I, though no details or timelines were disclosed.
- Peak revenue potential: At full capacity of 26,500 tons, peak revenue is estimated between INR 1,250 and 1,300 crores, implying an additional INR 550 to 600 crores over current levels.
- Utilization confidence is customer-backed: Management is confident of achieving almost 60% capacity utilization on the new project by 2024-2025 because existing customers have already expressed a desire to buy more product if the company can deliver it.
- Existing capacity buys time: Current capacity is sufficient to maintain business momentum for the next year while operating at optimal levels.
- Margin expectations on new capacity: EBITDA margins on new capacity should be similar to current levels and possibly better due to resource optimization.
Yayesh Jhaveri: "We already have the, it is just in the initial phase, we are only doing on the industrial products and the products that we are manufacturing currently. So it's just the capacity expansion, and we already have our customers shown us the desire to buy more product if we can deliver."
Balance Sheet & Capital Allocation
- Working capital cycle steady: The working capital cycle is expected to remain at 95 to 100 days.
- Debt repayment direction set, details withheld: Directionally, the plan is to repay debt as new capacity comes up, but management declined to disclose cash flow generation estimates or a specific repayment schedule, stating they would disclose "once we reach that time."
- Debt awareness acknowledged: Management stated it is aware of high debt levels and will "take care of things wisely" while maintaining margins.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 revenue growth | 10% to 15% growth with continued margin and return improvement | FY23 |
| Phase I commercialization | New project at Pakhajan operational | After end of 2023 or early 2024 |
| Phase I capacity utilization | Achieve ~60% utilization on new capacity | By 2024-2025 |
| Peak revenue from expansion | INR 1,250–1,300 crores at full 26,500-ton capacity | At full utilization (undated) |
| Working capital cycle | Maintain at 95–100 days | Ongoing |
| Product mix shift | Continue shifting toward industrial products to sustain margins | Ongoing |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹192.4 cr, +40.2% YoY |
| Overseas revenue share | >69% of total revenue |
| Industrial chemicals revenue share | >80% of total revenue |
| Consumer chemicals revenue share | ~20% of total revenue |
| EBITDA margin | 18%, improved from 13% over the last 10 quarters |
| EBITDA margin (analyst reference) | 16% (analyst stated 16%; management did not confirm this figure) |
| FY23 revenue growth guidance | 10% to 15% |
| Phase I capacity addition | 15,500 MTPA, total capacity to reach ~26,500 MTPA |
| Phase I cash capex incurred (H1 FY23) | ₹64 cr |
| Peak revenue estimate at full capacity | ₹1,250–1,300 cr, implying additional ₹550–600 cr |
| Capex funding: bank loans | ₹240 cr |
| Capex funding: internal accruals | ₹110 cr |
| Total debt post capex | ~₹450 cr (per an analyst's math, which management acknowledged as approximately correct) |
| Working capital cycle | 95–100 days, currently ~100 days |
| Raw material inventory holding | ~2 months |
| New project commercialization timeline | End of 2023 or early 2024 |
| Products registered under REACH | >40 |
| Clients served | 2,000+ |
| Permanent employees | 580+ |
| Global country presence | 50+ countries |